Kenneth Krogulski’s Form 4 filing history paints a picture of an insider whose activity is dominated by compensation and administrative adjustments rather than discretionary market moves. Across 150 reported transactions, he has recorded zero open-market sales and only $14,901.58 in open-market purchases, a figure dwarfed by the $16,240 in grants and awards (code “A”) he received. The most recent of those awards came on March 18, 2026, when he was granted $11,200 and $5,040 in Cumberland Pharmaceuticals (CPIX) shares, suggesting his stake is being built primarily through issuer compensation rather than personal capital outlay.
The bulk of his recent filings, however, consist of small “L” transactions—likely routine dividend or interest equivalents—clustered daily in CPIX between late November and the end of December 2025. These range from roughly $212 to $340 per event, with a steady cadence of one per trading day, cumulatively adding a few thousand dollars in value over the period. The pattern is mechanical and passive, reflecting automatic accruals rather than conviction-based buying or selling.
Notably, Krogulski’s record shows no recent sales of any kind—no code “S” dispositions, no returns to the issuer, and no tax-withholding events in the visible window. His total sell value stands at zero, and even his acquisition activity is almost entirely non-discretionary. The absence of open-market purchases or sales in the recent stretch, combined with the steady drip of small “L” credits and periodic grants, indicates an insider who is accumulating slowly through corporate actions while refraining from any decisive bullish or bearish positioning in the open market.
AI-assisted summary